Spanish Government Contributes One Million Euro for AIDS Vaccine Development
June 14, 2007
The International AIDS Vaccine Initiative (IAVI) and the Spanish AIDS NGO grupo de Trabajo sobre tratamientos del VIH (gTt) are grateful to the Spanish government for their one-year contribution of one million Euro to IAVI for the development of an AIDS vaccine. Leire Pajin, the Secretary of State for International Cooperation, made the announcement about the new appropriation during an international seminar on AIDS vaccines in Madrid. This is the first grant from the Spanish government to IAVI.
“We are very grateful to the Spanish government for making such an important contribution to our organization,” said Frans van den Boom, Vice President of IAVI’s European Programme. “It strengthens Europe’s leading role with now eight governments and the EU supporting the development of an AIDS vaccine.”
Despite efforts to control the AIDS epidemic, every day another 12,000 people become newly infected with HIV. The vast majority of these people live in developing countries, and many are women and girls.
The development of AIDS vaccines is an essential component in the global response to the AIDS pandemic. Access to available treatment and care is vitally important, but with the same urgency investments are also required in new AIDS prevention technologies, such as vaccines and microbicides.
The support from the Spanish and other governments allows IAVI to address some of the most critical questions in AIDS vaccine science, to continue clinical testing of promising AIDS vaccine candidates, to build infrastructure for research and development in India and African countries and to prepare communities for larger-scale AIDS vaccine clinical trials.
“This announcement is the result of joint advocacy efforts by Spanish AIDS and development NGOs, members of parliament and IAVI that have been sustained over the past years,” said Joan Tallada, General Coordinator of gTt. “We are very proud that the Spanish government is making funds available to IAVI for the development of an AIDS vaccine. It is our hope that Spain will continue to partner with us over the long-term in our efforts to find a vaccine.”
History has shown that vaccines are extremely effective in controlling infectious diseases, and an AIDS vaccine, once available, will have a major impact on the AIDS epidemic. Estimates suggest even a partially effective AIDS vaccine distributed to just 30% of the population would cut 17 million new infections over the course of 15 years, an important step to eradicating AIDS over the coming decades.
The International AIDS Vaccine Initiative (IAVI) is a global not-for-profit organization whose mission is to ensure the development of safe, effective, accessible, preventive HIV vaccines for use throughout the world. Founded in 1996 and operational in 24 countries, IAVI and its network of collaborators research and develop vaccine candidates. IAVI's financial and in-kind supporters include the Alfred P. Sloan Foundation, the Bill & Melinda Gates Foundation, the Foundation for the National Institutes of Health, The John D. Evans Foundation, The New York Community Trust, the James B. Pendleton Charitable Trust, The Rockefeller Foundation, The Starr Foundation, The William and Flora Hewlett Foundation; the Governments of Canada, Denmark, Ireland, The Netherlands, Norway, Sweden, the United Kingdom, and the United States, the Basque Autonomous Government as well as the European Union; multilateral organizations such as The World Bank; corporate donors including BD (Becton, Dickinson & Co.), Continental Airlines, Google Inc., Henry Schein, Inc., Merck & Co., Inc. and Pfizer Inc; leading AIDS charities such as Broadway Cares/Equity Fights AIDS and Until There's A Cure Foundation; other private donors such as The Haas Trusts; and many generous individuals from around the world. For more information, see www.iavi.org.
gTt is an non-governmental organization created in 1997 with the objective to improve the life expectancy and quality of people living with HIV or at risk of acquiring the infection, as a way to contribute to a fairer, more equitable and integrated society. Currently the gTt team has 14 permanent professionals and more than 20 regular collaborators. gTt’s headquarters is in Barcelona, Spain and its area of influence extends through all of Spain and other Spanish-speaking countries. For more information, see www.gtt-vih.org